0001193125-22-197362.txt : 20220720 0001193125-22-197362.hdr.sgml : 20220720 20220720060632 ACCESSION NUMBER: 0001193125-22-197362 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220720 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220720 DATE AS OF CHANGE: 20220720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 221092709 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 8-K 1 d383286d8k.htm 8-K 8-K
false 0001156039 0001156039 2022-07-20 2022-07-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 20, 2022

 

 

Elevance Health, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Indiana   001-16751   35-2145715

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

220 Virginia Ave

Indianapolis, IN 46204

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (800) 331-1476

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock   ELV   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On July 20, 2022, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

None of the information furnished in Item 2.02 or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Exhibit

99.1    Press Release, dated July 20, 2022, reporting Elevance Health, Inc. financial results for the quarter ended June 30, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

FORWARD-LOOKING STATEMENTS

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal, state and international law and regulation, including changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; the impact of a cyber-attack or other cyber security breach resulting in unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management (“PBM”) business, including non-compliance by any party with the PBM

services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 20, 2022

 

ELEVANCE HEALTH, INC.
By:  

/s/ Kathleen S. Kiefer

Name:   Kathleen S. Kiefer
Title:   Corporate Secretary
 EX-99.1 2 d383286dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

LOGO

ELEVANCE HEALTH REPORTS SECOND QUARTER 2022 RESULTS,

RAISES FULL YEAR OUTLOOK

 

  •  

Second quarter GAAP net income was $6.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $8.04* per share.

 

  •  

Operating revenue grew 15.6% over the prior year quarter to $38.5 billion.

 

  •  

Operating gain grew 13.7% over the prior year quarter to $2.4 billion.

 

  •  

Medical enrollment increased 2.7 million members year-over-year and 276 thousand members during the quarter to 47.1 million members.

 

  •  

Third quarter 2022 dividend of $1.28 per share declared to shareholders.

Indianapolis, Ind.—July 20, 2022—Elevance Health, Inc. (NYSE: ELV) reported second quarter 2022 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share.

“The disciplined execution of our strategy, and the balance and resilience of our diversified portfolio of businesses has enabled us to deliver another quarter of strong organic growth, and we have raised our outlook for 2022 earnings per share as a result,” said Gail K. Boudreaux, President and CEO. “Our recent name change to Elevance Health and the broader rebranding strategy underscores our transformation to a lifetime, trusted health partner and our diversified set of businesses that lend resilience in any business environment. We are uniquely well-positioned for growth in the future as we remain focused on meeting the needs of our clients and customers.”

The Company now expects GAAP net income to be greater than $25.28 per share, including approximately $3.42 per share of net unfavorable items. The Company now expects full-year adjusted net income to be greater than $28.70 per share, based on stronger than expected results year-to-date.

 

*

Refer to GAAP reconciliation tables on page 14.

 

1

CONSOLIDATED HIGHLIGHTS

Earnings Per Share: GAAP net income was $6.79 per share in the second quarter, including net negative adjustment items of $1.25 per share. Adjusted net income was $8.04* per share, up 14.4% from $7.03 in the same period a year ago.

 

*

Please refer to the GAAP reconciliation tables on page 14.

Membership: Medical enrollment totaled approximately 47.1 million members as of June 30, 2022, an increase of 2.7 million, or 6.1 percent from the prior year quarter. Government Business enrollment increased by 1.6 million lives compared to the prior year quarter, primarily driven by organic growth in the Medicaid business, aided by the suspension of eligibility recertification efforts in our markets, the launch of Healthy Blue in North Carolina, the acquisitions of Paramount Advantage and Integra Managed Care and organic growth in Medicare Advantage. Commercial & Specialty Business enrollment increased by 1.2 million year over year primarily driven by strong sales in both fee-based and risk-based businesses.

During the second quarter of 2022, medical enrollment increased by 276 thousand lives driven by organic growth in Medicaid due to suspension of eligibility recertification, higher BlueCard activity and the acquisition of Integra Managed Care, which added 43 thousand members.

Operating Revenue: Operating revenue was $38.5 billion in the second quarter of 2022, an increase of $5.2 billion, or 15.6 percent, from the prior year quarter. The increase was driven by higher premium revenue due to membership growth in Medicaid, the acquisitions of MMM and Paramount Advantage, as well as premium rate increases to cover overall cost trends and growth in Medicare Advantage and Commercial risk-based membership. The increase in operating revenue was further attributable to the growth in pharmacy product revenue within IngenioRx, the acquisition of Integra Managed Care and the launch of Healthy Blue in North Carolina.

Benefit Expense Ratio: The benefit expense ratio was 87.0 percent in the second quarter of 2022, an increase of 20 basis points over the prior year quarter. The increase was primarily driven by a shift in mix of business driven by faster growth in Government programs, which have a higher benefit expense ratio, as compared to growth in the Commercial & Specialty risk business, which represented 27% of premium revenue in the second quarter, down from 29% in the prior year quarter.

Medical claims reserves established at December 31, 2021 developed in line with the Company’s expectations as of the second quarter of 2022.

Days in Claims Payable: Days in Claims Payable was 47.8 days as of June 30, 2022, an increase of 0.9 days from March 31, 2022 and a decrease of 0.3 days compared to June 30, 2021. The timing of certain provider pass-through payments and corresponding reserves set in the current year had the effect of increasing Days in Claims Payable by 1.8 days, which we expect will reverse in the third quarter, while the timing of the acquisitions of MMM and myNEXUS increased Days in Claims Payable by 1.6 days in the second quarter of 2021.

 

2

SG&A Expense Ratio: The SG&A expense ratio was 11.1 percent in the second quarter of 2022, a decrease of 40 basis points from 11.5 percent in the second quarter of 2021. The decrease was primarily driven by operating expense leverage associated with growth in operating revenue, partially offset by increased spend to support growth.

Operating Cash Flow: Operating cash flow was approximately $2.5 billion, or 1.5 times net income in the second quarter of 2022, an increase of $769 million as compared to the prior year quarter. The year-on-year increase was driven by the impact of working capital changes, including the timing of certain provider pass-through payments.

Share Repurchase Program: During the second quarter of 2022, the Company repurchased 1.3 million shares of its common stock for $624 million, at a weighted average price of $489.07. Year-to-date, as of the end of the second quarter, the Company repurchased 2.5 million shares of its common stock for $1.2 billion, at a weighted average price of $471.72. As of June 30, 2022, the Company had approximately $3.0 billion of Board-approved share repurchase authorization remaining.

Cash Dividend: During the second quarter of 2022, the Company paid a quarterly dividend of $1.28 per share, representing a distribution of cash totaling $309 million.

On July 19, 2022, the Audit Committee of the Company’s Board of Directors declared a third quarter 2022 dividend to shareholders of $1.28 per share. The third quarter dividend is payable on September 23, 2022, to shareholders of record at the close of business on September 9, 2022.

Investment Portfolio & Capital Position: During the second quarter of 2022, the Company recorded net losses of $231 million. During the second quarter of 2021, the Company recorded net gains of $172 million. These amounts are excluded from adjusted earnings per share.

As of June 30, 2022, the Company’s net unrealized loss position in the investment portfolio was $2.0 billion, consisting primarily of fixed maturity securities. As of June 30, 2022 cash and investments at the parent company totaled approximately $948 million.

 

3

REPORTABLE SEGMENTS

Elevance Health has four reportable segments: Commercial & Specialty Business (comprised of Individual, Group risk-based, Group fee-based, and BlueCard businesses); Government Business (comprised of the Medicaid, Medicare, and Federal Health Products & Services businesses); IngenioRx; and Other (comprised of the Carelon companies, formerly known as our Diversified Business Group, and corporate expenses not allocated to our other reportable segments).

Elevance Health, Inc.

Reportable Segment Highlights

(Unaudited)

 

(In millions)    Three Months Ended June 30     Six Months Ended June 30  
     2022     2021     Change     2022     2021     Change  

Operating Revenue

             

Commercial & Specialty Business

    $ 10,561     $ 9,550       10.6 %    $ 20,830     $ 19,041       9.4 % 

Government Business

      23,835       20,066       18.8 %      47,593       39,349       21.0 % 

IngenioRx

      7,071       6,219       13.7 %      13,754       12,081       13.8 % 

Other

      3,298       2,517       31.0 %      6,519       4,887       33.4 % 

Eliminations

      (6,283 )      (5,073 )      23.9 %      (12,328 )      (9,981 )      23.5 % 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total Operating Revenue1

    $ 38,482     $ 33,279       15.6 %    $ 76,368     $ 65,377       16.8 % 

Operating Gain

             

Commercial & Specialty Business

    $ 806     $ 791       1.9 %    $ 1,888     $ 2,059       (8.3 )% 

Government Business

      996       868       14.7 %      1,785       1,346       32.6 % 

IngenioRx

      479       405       18.3 %      877       812       8.0 % 

Other

      86       17       405.9 %      264       25       956.0 % 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total Operating Gain1

    $ 2,367     $ 2,081       13.7 %    $ 4,814     $ 4,242       13.5 % 

Operating Margin

             

Commercial & Specialty Business

      7.6 %      8.3 %      (70 ) bp      9.1 %      10.8 %      (170 ) bp 

Government Business

      4.2 %      4.3 %      (10 ) bp      3.8 %      3.4 %      40  bp 

IngenioRx

      6.8 %      6.5 %      30  bp      6.4 %      6.7 %      (30 ) bp 

Total Operating Margin1

      6.2 %      6.3 %      (10 ) bp      6.3 %      6.5 %      (20 ) bp 

 

1.

See “Basis of Presentation” on page 6 herein.

2.

“NM” = calculation not meaningful.

Commercial & Specialty Business: Operating gain in the Commercial & Specialty Business segment totaled $806 million in the second quarter of 2022, an increase of $15 million from $791 million in the second quarter of 2021. The increase was primarily driven by the positive contribution from growth in risk- and fee-based membership, partially offset by the net unfavorable effect of COVID.

Government Business: Operating gain in the Government Business segment was $996 million in the second quarter of 2022, an increase of $128 million from $868 million in the second quarter of 2021. The increase was primarily attributable to premium rates in Medicare that better reflect the acuity of our members and membership growth in Medicaid.

IngenioRx: Operating gain was $479 million in the second quarter of 2022, an increase of $74 million from $405 million in the second quarter of 2021. The increase was driven by an in-year out of period favorable adjustment and the impact of higher prescription volume associated with growth in integrated medical and pharmacy members.

 

4

Other: The Company reported an operating gain of $86 million in the Other segment for the second quarter of 2022, an increase of $69 million from $17 million in the prior year quarter. The increase was driven by improved performance in Carelon’s affiliated and unaffiliated earnings.

 

5

Basis of Presentation

 

1.

Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Refer to page 14 for the GAAP reconciliation tables.

 

2.

Operating margin is defined as operating gain divided by operating revenue.

Conference Call and Webcast

Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”) to discuss the company’s second quarter results and outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers:

 

       888-947-9963 (Domestic)    866-430-8797 (Domestic Replay)        
  312-470-0178 (International)    203-369-0943 (International Replay)   

The access code for today’s conference call is 3972058. The replay will be available from 11:30 a.m. EDT today, until the end of the day on August 20, 2022. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

 

Elevance Health Contacts:

   

Investor Relations

   

Media

Stephen Tanal

   

Leslie Porras

Stephen.Tanal@elevancehealth.com

   

Leslie.Porras@elevancehealth.com

 

6

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

 

7

Elevance Health, Inc.

Membership Summary

(Unaudited and in Thousands)

 

                          Change from  
     June 30,
2022		      June 30,
2021		      March 31,
2022		      June 30,
2021		     March 31,
2022		  

Medical Membership

              

Commercial & Specialty Business

              

Individual

      803        738        818        8.8 %      (1.8 )% 

Group Risk-Based

      4,020        3,851        4,028        4.4 %      (0.2 )% 
  

 

 

     

 

 

     

 

 

       

Commercial Risk-Based

      4,823        4,589        4,846        5.1 %      (0.5 )% 

BlueCard®

      6,445        6,235        6,370        3.4 %      1.2 % 

Group Fee-Based

      20,086        19,372        20,148        3.7 %      (0.3 )% 
  

 

 

     

 

 

     

 

 

       

Commercial Fee-Based

      26,531        25,607        26,518        3.6 %      —   % 
  

 

 

     

 

 

     

 

 

       

Total Commercial & Specialty Business

      31,354        30,196        31,364        3.8 %      —   % 

Government Business

              

Medicare Advantage

      1,946        1,824        1,921        6.7 %      1.3 % 

Medicare Supplement

      942        936        939        0.6 %      0.3 % 
  

 

 

     

 

 

     

 

 

       

Total Medicare

      2,888        2,760        2,860        4.6 %      1.0 % 

Medicaid

      11,181        9,754        10,919        14.6 %      2.4 % 

Federal Employees Health Benefits

      1,628        1,631        1,632        (0.2 )%      (0.2 )% 
  

 

 

     

 

 

     

 

 

       

Total Government Business

      15,697        14,145        15,411        11.0 %      1.9 % 
  

 

 

     

 

 

     

 

 

       

Total Medical Membership

      47,051        44,341        46,775        6.1 %      0.6 % 
  

 

 

     

 

 

     

 

 

       

Other Membership

              

Life and Disability Members

      4,779        4,732        4,679        1.0 %      2.1 % 

Dental Members

      6,620        6,606        6,649        0.2 %      (0.4 )% 

Dental Administration Members

      1,589        1,497        1,588        6.1 %      0.1 % 

Vision Members

      9,385        7,819        9,211        20.0 %      1.9 % 

Medicare Part D Standalone Members

      276        433        279        (36.3 )%      (1.1 )% 

 

8

Elevance Health, Inc.

Consolidated Statements of Income

(Unaudited)

 

(In millions, except per share data)    Three Months Ended
June 30		        
     2022     2021     Change  

Revenues

       

Premiums

    $ 33,076     $ 28,533       15.9 % 

Product revenue

      3,568       3,042       17.3 % 

Administrative fees and other revenue

      1,838       1,704       7.9 % 
  

 

 

    

 

 

    

Total operating revenue

      38,482       33,279       15.6 % 

Net investment income

      381       400       (4.8 )% 

Net (losses) gains on financial instruments

      (231 )      172       (234.3 )% 
  

 

 

    

 

 

    

Total revenues

      38,632       33,851       14.1 % 

Expenses

       

Benefit expense

      28,777       24,763       16.2 % 

Cost of products sold

      3,069       2,614       17.4 % 

Selling, general and administrative expense

      4,269       3,821       11.7 % 

Interest expense

      208       205       1.5 % 

Amortization of other intangible assets

      166       90       84.4 % 

Loss on extinguishment of debt

      —         5       (100.0 )% 
  

 

 

    

 

 

    

Total expenses

      36,489       31,498       15.8 % 
  

 

 

    

 

 

    

Income before income tax expense

      2,143       2,353       (8.9 )% 

Income tax expense

      493       552       (10.7 )% 
  

 

 

    

 

 

    

Net income

      1,650       1,801       (8.4 )% 

Net loss/(income) attributable to noncontrolling interests

      3       (8 )      NM  
  

 

 

    

 

 

    

Shareholders’ net income

    $ 1,653     $ 1,793       (7.8 )% 
  

 

 

    

 

 

    

Shareholders’ net income per diluted share

    $ 6.79     $ 7.25       (6.3 )% 
  

 

 

    

 

 

    

Diluted shares

      243.4       247.4       (1.6 )% 

Benefit expense as a percentage of premiums

      87.0 %      86.8 %      20 bp  

Selling, general and administrative expense as a percentage of total operating revenue

      11.1 %      11.5 %      (40 ) bp 

Income before income tax expense as a percentage of total revenue

      5.5 %      7.0 %      (150 ) bp 

“NM” = calculation not meaningful

 

9

Elevance Health, Inc.

Consolidated Statements of Income

(Unaudited)

 

(In millions, except per share data)    Six Months Ended
June 30		        
     2022     2021     Change  

Revenues

       

Premiums

    $ 65,861     $ 56,209       17.2 % 

Product revenue

      6,869       5,779       18.9 % 

Administrative fees and other revenue

      3,638       3,389       7.3 % 
  

 

 

    

 

 

    

Total operating revenue

      76,368       65,377       16.8 % 

Net investment income

      741       691       7.2 % 

Net (losses) gains on financial instruments

      (382 )      168       (327.4 )% 
  

 

 

    

 

 

    

Total revenues

      76,727       66,236       15.8 % 

Expenses

       

Benefit expense

      56,992       48,462       17.6 % 

Cost of products sold

      5,952       4,927       20.8 % 

Selling, general and administrative expense

      8,610       7,746       11.2 % 

Interest expense

      409       397       3.0 % 

Amortization of other intangible assets

      295       170       73.5 % 

Loss on extinguishment of debt

      —         5       (100.0 )% 
  

 

 

    

 

 

    

Total expenses

      72,258       61,707       17.1 % 
  

 

 

    

 

 

    

Income before income tax expense

      4,469       4,529       (1.3 )% 

Income tax expense

      1,024       1,061       (3.5 )% 
  

 

 

    

 

 

    

Net income

      3,445       3,468       (0.7 )% 

Net loss/(income) attributable to noncontrolling interests

      13       (10 )      NM  
  

 

 

    

 

 

    

Shareholders’ net income

    $ 3,458     $ 3,458       —   % 
  

 

 

    

 

 

    

Shareholders’ net income per diluted share

    $ 14.18     $ 13.95       1.6 % 
  

 

 

    

 

 

    

Diluted shares

      243.9       247.8       (1.6 )% 

Benefit expense as a percentage of premiums

      86.5 %      86.2 %      30 bp  

Selling, general and administrative expense as a percentage of total operating revenue

      11.3 %      11.8 %      (50 ) bp 

Income before income tax expense as a percentage of total revenue

      5.8 %      6.8 %      (100 ) bp 

“NM” = calculation not meaningful

 

10

Elevance Health, Inc.

Consolidated Balance Sheets

 

(In millions)    June 30,
2022		     December 31,
2021		  
     (Unaudited)        

Assets

     

Current assets:

     

Cash and cash equivalents

    $ 6,456     $ 4,880  

Fixed maturity securities

      25,765       26,267  

Equity securities, current

      1,572       1,881  

Premium receivables

      6,757       5,681  

Self-funded receivables

      3,844       4,010  

Other receivables

      3,600       3,749  

Other current assets

      5,661       4,654  
  

 

 

    

 

 

  

Total current assets

      53,655       51,122  

Long-term investments:

     

Fixed maturity securities

      603       632  

Other invested assets

      5,398       5,225  

Property and equipment, net

      4,090       3,919  

Goodwill

      24,367       24,228  

Other intangible assets

      10,762       10,615  

Other noncurrent assets

      2,002       1,719  
  

 

 

    

 

 

  

Total assets

    $ 100,877     $ 97,460  
  

 

 

    

 

 

  

Liabilities and equity

     

Liabilities

     

Current liabilities:

     

Medical claims payable

    $ 15,127     $ 13,518  

Other policyholder liabilities

      5,577       5,521  

Unearned income

      971       1,153  

Accounts payable and accrued expenses

      5,850       4,970  

Short-term borrowings

      175       275  

Current portion of long-term debt

      2,248       1,599  

Other current liabilities

      9,360       7,849  
  

 

 

    

 

 

  

Total current liabilities

      39,308       34,885  

Long-term debt, less current portion

      21,165       21,157  

Reserves for future policy benefits

      822       802  

Deferred tax liabilities, net

      2,021       2,805  

Other noncurrent liabilities

      1,694       1,683  
  

 

 

    

 

 

  

Total liabilities

      65,010       61,332  
  

 

 

    

 

 

  

Shareholders’ equity

     

Common stock

      2       2  

Additional paid-in capital

      9,134       9,148  

Retained earnings

      28,825       27,088  

Accumulated other comprehensive loss

      (2,149 )      (178 ) 
  

 

 

    

 

 

  

Total shareholders’ equity

      35,812       36,060  

Noncontrolling interests

      55       68  
  

 

 

    

 

 

  

Total equity

      35,867       36,128  
  

 

 

    

 

 

  

Total liabilities and equity

    $ 100,877     $ 97,460  
  

 

 

    

 

 

  

 

11

Elevance Health, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

(In millions)    Six Months Ended June 30  
     2022     2021  

Operating activities

     

Net income

    $ 3,445     $ 3,468  

Adjustments to reconcile net income to net cash provided by operating activities:

     

Net losses (gains) on financial instruments

      382       (168 ) 

Equity in net earnings of other invested assets

      (258 )      (309 ) 

Depreciation and amortization

      751       591  

Deferred income taxes

      (172 )      (8 ) 

Share-based compensation

      122       133  

Changes in operating assets and liabilities:

     

Receivables, net

      (662 )      (1,632 ) 

Other invested assets

      32       (44 ) 

Other assets

      (419 )      (247 ) 

Policy liabilities

      1,514       1,912  

Unearned income

      (182 )      (180 ) 

Accounts payable and other liabilities

      632       560  

Income taxes

      (159 )      106  

Other, net

      (33 )      6  
  

 

 

    

 

 

  

Net cash provided by operating activities

      4,993       4,188  

Investing activities

     

Purchases of investments

      (13,253 )      (11,221 ) 

Proceeds from sale of investments

      7,140       6,345  

Maturities, calls and redemptions from investments

      4,347       2,246  

Changes in securities lending collateral

      (620 )      (642 ) 

Purchases of subsidiaries, net of cash acquired

      (609 )      (3,442 ) 

Purchases of property and equipment

      (549 )      (489 ) 

Other, net

      (58 )      (29 ) 
  

 

 

    

 

 

  

Net cash used in investing activities

      (3,602 )      (7,232 ) 

Financing activities

     

Net proceeds from commercial paper borrowings

      250       300  

Net proceeds from (repayments of) short-term borrowings

      (100 )      175  

Net proceeds from long-term borrowings

      357       2,510  

Changes in securities lending payable

      620       642  

Changes in bank overdrafts

      817       364  

Repurchase and retirement of common stock

      (1,169 )      (927 ) 

Cash dividends

      (618 )      (555 ) 

Proceeds from issuance of common stock under employee stock plans

      116       141  

Taxes paid through withholding of common stock under employee stock plans

      (88 )      (93 ) 

Other, net

      10       11  
  

 

 

    

 

 

  

Net cash provided by financing activities

      195       2,568  

Effect of foreign exchange rates on cash and cash equivalents

      (10 )      (7 ) 
  

 

 

    

 

 

  

Change in cash and cash equivalents

      1,576       (483 ) 

Cash and cash equivalents at beginning of period

      4,880       5,741  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 6,456     $ 5,258  
  

 

 

    

 

 

  

 

12

Elevance Health, Inc.

Reconciliation of Medical Claims Payable

 

     Six Months Ended June 30     Years Ended December 31  
     2022     2021     2021     2020     2019  
(In millions)    (Unaudited)     (Unaudited)                    

Gross medical claims payable, beginning of period

    $ 13,282     $ 11,135     $ 11,135     $ 8,647     $ 7,266  

Ceded medical claims payable, beginning of period

      (21 )      (46 )      (46 )      (33 )      (34 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Net medical claims payable, beginning of period

      13,261       11,089       11,089       8,614       7,232  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Business combinations and purchase adjustments

      133       420       420       339       —    

Net incurred medical claims:

           

Current year

      55,737       48,343       100,440       85,094       78,695  

Prior years redundancies(1)

      (972 )      (1,772 )      (1,703 )      (637 )      (500 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total net incurred medical claims

      54,765       46,571       98,737       84,457       78,195  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Net payments attributable to:

           

Current year medical claims

      42,882       37,533       88,156       74,629       70,294  

Prior years medical claims

      10,401       7,767       8,829       7,692       6,519  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total net payments

      53,283       45,300       96,985       82,321       76,813  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Net medical claims payable, end of period

      14,876       12,780       13,261       11,089       8,614  

Ceded medical claims payable, end of period

      13       41       21       46       33  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Gross medical claims payable, end of period

    $ 14,889     $ 12,821     $ 13,282     $ 11,135     $ 8,647  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Current year medical claims paid as a percentage of current year net incurred medical claims

      76.9 %      77.6 %      87.8 %      87.7 %      89.3 % 

Prior year redundancies in the current year as a percentage of prior year net medical claims payable less prior year redundancies in the current year

      7.9 %      19.0 %      18.1 %      8.0 %      7.4 % 

Prior year redundancies in the current year as a percentage of prior year net incurred medical claims

      1.0 %      2.1 %      2.0 %      0.8 %      0.7 % 

 

(1) 

Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.

 

13

Elevance Health, Inc.

GAAP Reconciliation

(Unaudited)

Elevance Health, Inc. has referenced “Adjusted Net Income” and “Adjusted Net Income Per Share,” which are non-GAAP measures, in this document. These non-GAAP measures are not intended to be alternatives to any measure calculated in accordance with GAAP. In addition to these non-GAAP measures, references are made to the measures “Operating Revenue” and “Operating Gain.” Each of these measures is provided to further aid investors in understanding and analyzing the company’s core operating results and comparing Elevance Health, Inc.’s financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable segments operating gain to income before income tax expense, is reported below. Prior amounts may be grouped differently to conform to current presentation.

 

     Three Months
Ended June 30		           Six Months Ended
June 30		        
(In millions, except per share data)    2022     2021     Change     2022     2021     Change  

Shareholders’ net income

    $ 1,653     $ 1,793       (7.8 )%    $ 3,458     $ 3,458       — % 

Add / (Subtract):

             

Net losses (gains) on financial instruments

      231       (172 )        382       (168 )   

Amortization of other intangible assets

      166       90         295       170    

Loss on extinguishment of debt

      —         5         —         5    

Transaction and integration related costs

      14       12         23       21    

Litigation expenses

      4       6         5       12    

Tax impact of non-GAAP adjustments

      (111 )      6         (189 )      (19 )   
  

 

 

    

 

 

      

 

 

    

 

 

    

Net adjustment items

      304       (53 )        516       21    
  

 

 

    

 

 

      

 

 

    

 

 

    

Adjusted shareholders’ net income

    $ 1,957     $ 1,740       12.5 %    $ 3,974     $ 3,479       14.2 % 
  

 

 

    

 

 

      

 

 

    

 

 

    

Shareholders’ net income per diluted share

    $ 6.79     $ 7.25       (6.3 )%    $ 14.18     $ 13.95       1.6 % 

Add / (Subtract):

             

Net losses (gains) on financial instruments

      0.95       (0.70 )        1.57       (0.68 )   

Amortization of other intangible assets

      0.68       0.36         1.21       0.69    

Loss on extinguishment of debt

      —         0.02         —         0.02    

Transaction and integration related costs

      0.06       0.05         0.09       0.08    

Litigation expenses

      0.02       0.02         0.02       0.05    

Tax impact of non-GAAP adjustments

      (0.46 )      0.02         (0.77 )      (0.08 )   

Rounding impact

      —         0.01         (0.01 )      0.01    
  

 

 

    

 

 

      

 

 

    

 

 

    

Net adjustment items

      1.25       (0.22 )        2.11       0.09    
  

 

 

    

 

 

      

 

 

    

 

 

    

Adjusted shareholders’ net income per diluted share

    $ 8.04     $ 7.03       14.4 %    $ 16.29     $ 14.04       16.0 % 
  

 

 

    

 

 

      

 

 

    

 

 

    
     Full Year 2022 Outlook                    

Shareholders’ net income per diluted share

      Greater than $25.28        

Add / (Subtract):

         

Net losses on financial instruments

      $1.57        

Transaction and integration related costs

      $0.09        

Litigation expenses

      $0.02        

Amortization of other intangible assets

      Approximately $3.07        

Tax impact of non-GAAP adjustments

      Approximately $(1.33)        
  

 

 

        

Net adjustment items

      Approximately $3.42        
  

 

 

        

Adjusted shareholders’ net income per diluted share

      Greater than $28.70        
  

 

 

        
     Three Months Ended
June 30		           Six Months Ended
June 30		        
(In millions)    2022     2021     Change     2022     2021     Change  

Income before income tax expense

    $ 2,143     $ 2,353       (8.9 )%    $ 4,469     $ 4,529       (1.3 )% 

Net investment income

      (381 )      (400 )        (741 )      (691 )   

Net losses (gains) on financial instruments

      231       (172 )        382       (168 )   

Interest expense

      208       205         409       397    

Amortization of other intangible assets

      166       90         295       170    

Loss on extinguishment of debt

      —         5         —         5    
  

 

 

    

 

 

      

 

 

    

 

 

    

Reportable segments operating gain

    $ 2,367     $ 2,081       13.7 %    $ 4,814     $ 4,242       13.5 % 
  

 

 

    

 

 

      

 

 

    

 

 

    

 

14

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal, state and international law and regulation, including changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; the impact of a cyber-attack or other cyber security breach resulting in unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management (“PBM”) business, including non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

 

15

EX-101.SCH 3 elv-20220720.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 elv-20220720_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 elv-20220720_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g383286g0719225712648.jpg GRAPHIC begin 644 g383286g0719225712648.jpg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end GRAPHIC 7 g383286page1.jpg GRAPHIC begin 644 g383286page1.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jul. 20, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001156039
Document Type 8-K
Document Period End Date Jul. 20, 2022
Entity Registrant Name Elevance Health, Inc.
Entity Incorporation State Country Code IN
Entity File Number 001-16751
Entity Tax Identification Number 35-2145715
Entity Address, Address Line One 220 Virginia Ave
Entity Address, City or Town Indianapolis
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46204
City Area Code (800)
Local Phone Number 331-1476
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ELV
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 9 d383286d8k_htm.xml IDEA: XBRL DOCUMENT 0001156039 2022-07-20 2022-07-20 false 0001156039 8-K 2022-07-20 Elevance Health, Inc. IN 001-16751 35-2145715 220 Virginia Ave Indianapolis IN 46204 (800) 331-1476 false false false false Common Stock ELV NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d383286d8k.htm d383286dex991.htm elv-20220720.xsd elv-20220720_lab.xml elv-20220720_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d383286d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d383286d8k.htm" ] }, "labelLink": { "local": [ "elv-20220720_lab.xml" ] }, "presentationLink": { "local": [ "elv-20220720_pre.xml" ] }, "schema": { "local": [ "elv-20220720.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "elv", "nsuri": "http://imetrix.edgar-online.com/20220720", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d383286d8k.htm", "contextRef": "duration_2022-07-20_to_2022-07-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d383286d8k.htm", "contextRef": "duration_2022-07-20_to_2022-07-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220720/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-197362-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-197362-xbrl.zip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